Literature DB >> 17133253

Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis.

Lazaros I Sakkas1, Ian C Chikanza, Chris D Platsoucas.   

Abstract

Systemic sclerosis is characterized by extensive fibrosis, microvascular stenosis and autoantibody production. All three characteristics can be accounted for by activation of cells of the immune system. Activation of T cells is antigen-driven and occurs early in the course of the disease, before microscopic evidence of fibrosis. Activated T cells are predominantly of the type 2 T-helper lineage, and produce interleukin-4 and interleukin-13, which induce fibrosis. B cells are also activated early in the course of the disease and, through the production of autoantibodies, cause fibroblasts to adopt a profibrotic phenotype. Macrophages in perivascular infiltrates are activated and produce CC-chemokine ligand 2, transforming growth factor beta and platelet derived growth factor, all of which promote fibrosis and fibroproliferation. These new insights have direct impact on the treatment of patients with systemic sclerosis; therapies that target T cells, B cells and their harmful mediators are a logical approach, and preliminary data are promising.

Entities:  

Mesh:

Year:  2006        PMID: 17133253     DOI: 10.1038/ncprheum0346

Source DB:  PubMed          Journal:  Nat Clin Pract Rheumatol        ISSN: 1745-8382


  48 in total

Review 1.  Vasculopathy in scleroderma.

Authors:  Yoshihide Asano; Shinichi Sato
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

2.  Proteasome inhibition prevents development of experimental dermal fibrosis.

Authors:  Suleyman Serdar Koca; Metin Ozgen; Ferda Dagli; Mehmet Tuzcu; Ibrahim Hanifi Ozercan; Kazim Sahin; Ahmet Isik
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

3.  Aneurysmal lesions of patients with abdominal aortic aneurysm contain clonally expanded T cells.

Authors:  Song Lu; John V White; Wan Lu Lin; Xiaoying Zhang; Charalambos Solomides; Kyle Evans; Nectaria Ntaoula; Ifeyinwa Nwaneshiudu; John Gaughan; Dimitri S Monos; Emilia L Oleszak; Chris D Platsoucas
Journal:  J Immunol       Date:  2014-04-21       Impact factor: 5.422

Review 4.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 5.  Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future.

Authors:  Luca Cantarini; Donato Rigante; Antonio Vitale; Salvatore Napodano; Lazaros I Sakkas; Dimitrios P Bogdanos; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

Review 6.  Early systemic sclerosis-opportunities for treatment.

Authors:  Lazaros I Sakkas; Theodora Simopoulou; Christina Katsiari; Dimitrios Bogdanos; Ian C Chikanza
Journal:  Clin Rheumatol       Date:  2015-02-26       Impact factor: 2.980

Review 7.  Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis.

Authors:  S Kumar; J Singh; S Rattan; A J DiMarino; S Cohen; S A Jimenez
Journal:  Aliment Pharmacol Ther       Date:  2017-02-09       Impact factor: 8.171

8.  Cyclophosphamide treatment improves microvessel damage in systemic sclerosis.

Authors:  Paola Caramaschi; Alessandro Volpe; Sara Pieropan; Ilaria Tinazzi; Helal Mahamid; Lisa Maria Bambara; Domenico Biasi
Journal:  Clin Rheumatol       Date:  2008-12-04       Impact factor: 2.980

Review 9.  Helicobacter pylori and autoimmune disease: cause or bystander.

Authors:  Daniel S Smyk; Andreas L Koutsoumpas; Maria G Mytilinaiou; Eirini I Rigopoulou; Lazaros I Sakkas; Dimitrios P Bogdanos
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

10.  Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.

Authors:  Dimitrios Daoussis; Stamatis-Nick C Liossis; Athanassios C Tsamandas; Christina Kalogeropoulou; Alexandra Kazantzi; Chaido Sirinian; Maria Karampetsou; Georgios Yiannopoulos; Andrew P Andonopoulos
Journal:  Rheumatology (Oxford)       Date:  2009-05-15       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.